代表性论文: [1] 1 “Pharmacologic activation of p53 triggers viral mimicry response thereby abolishing tumor immune evasion and promoting anti-tumor immunity”; Cancer Discovery (影响因子38.2,中科院一区top期刊); 12期(封面文章); 2021;3090-3105; Zhou, X., M. Singh, G. Sanz Santos, V. Guerlavais, L. A. Carvajal, M. Aivado, Y. Zhan, M. M. S. Oliveira, L. S. Westerberg, D. A. Annis, J. I. Johnsen and G. Selivanova. [2] “Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246”; British Journal of Cancer (影响因子9.07,中科院一区top期刊); 11期; 2022; 2060-2071; Zhou, X., G. S. Santos, Y. Zhan, M. M. S. Oliveira, S. Rezaei, M. Singh, S. Peuget, L. S. Westerberg, J. I. Johnsen and G. Selivanova. [3] “Translating p53-based therapies for cancer into the clinic”; Sylvain Peuget, and Xiaolei Zhou, Galina Selivanova,. Nature Reviews Cancer (影响因子78.5,,中科院1区top期刊); 24期, 2024,192-215。 [4] “An ELISA method detecting the active form of suPAR.” Talanta (影响因子6.556,中科院1区top期刊); 卷号160; 2016; 205-210; Zhou, X., M. Xu, H. Huang, A. Mazar, Z. Iqbal, C. Yuan and M. Huang. [5] “A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging”; Acta Biomaterialia (影响因子10.633,中科院1区top期刊); 卷号23; 2015; 116-126; Zhou, X., K. Zheng, R. Li, Z. Chen, C. Yuan, P. Hu, J. Chen, J. Xue and M. Huang. [6] “Decreased DNA Damage and Improved p53 Specificity of RITA Analogs”; Molecular Cancer Therapeutics(影响因子6.006,中科院2区); 10期; 2022; 1524-1534; Zhan, Y., X. L. Zhou, S. Peuget, M. Singh, B. D. Peyser, Z. M. Fan and G. Selivanova. [7] “Identification and targeting of selective vulnerability rendered by tamoxifen resistance"; Breast Cancer Research (影响因子8.408,中科院1区top期刊);; issue 1; 2020; 80; Singh, M., X. Zhou, X. Chen, G. S. Santos, S. Peuget, Q. Cheng, A. Rihani, E. S. J. Arner, J. Hartman and G. Selivanova |